Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
53 studies found for:    Open Studies | "Thalassemia"
Show Display Options
Rank Status Study
21 Recruiting Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Conditions: Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
Interventions: Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Radiotherapy
22 Recruiting Pilot Study Evaluating Safety & Efficacy of a DCBT: NiCord® & UNM CBU to SCD Patients After Myeloablative Therapy
Condition: Sickle Cell Disease & Thalassemia
Intervention: Drug: NiCord
23 Recruiting Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major
Condition: AL-Hijama in Thalassmia Major
Interventions: Procedure: Al-hijamah;   Drug: Deferasirox
24 Recruiting Use of Mobile Technology for Intensive Training in Medication Management
Conditions: Sickle Cell Disease;   Thalassemia
Interventions: Behavioral: Video recording;   Behavioral: Medication Administration Log;   Behavioral: Education
25 Recruiting Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients
Condition: Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia
Intervention: Drug: Plerixafor
26 Recruiting QST-Pupillometry in Sickle Cell Disease Patients
Condition: SCD With Severe Phenotype (HbSS, HbSβ0 Thalassemia, HbSOARab)
Intervention: Other: Quantitative sensory testing
27 Recruiting Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Condition: Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions: Drug: Montelukast added to Hydroxyurea;   Drug: Placebo added to Hydroxyurea
28 Recruiting Bone Marrow for Hemoglobinopathy Research
Conditions: Sickle Cell Anemia;   Thalassemia
Intervention:
29 Recruiting Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies
Conditions: Sickle Cell Disease;   Thalassemia
Intervention: Biological: CordIn
30 Recruiting B-Thalasaemia Trait and Its Possible Cardioprotective Role
Conditions: Beta-Thalassemia Trait;   Coronary Artery Disease
Intervention:
31 Recruiting Stem Cell Transplant for Patients With Sickle Cell Disease (SCD), Thalassemia, Diamond Blackfan Anemia (DBA) and Other Non-malignant (Non-cancerous) Hematologic Disorders
Conditions: Sickle Cell Disease;   Thalassemia;   Diamond Blackfan Anemia;   Non-malignant Hematologic Disorders
Interventions: Drug: Anti-thymocyte globulin (ATG);   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: total body irradiation
32 Recruiting HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Conditions: Sickle Cell Disease;   Beta Thalassemia-Major
Interventions: Drug: alemtuzumab (Campath IH);   Drug: Fludarabine;   Drug: Melphalan;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Biological: Hematopoietic Stem Cell Transplantation
33 Recruiting Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study
Conditions: Sickle Cell Anemia;   Sickle Cell β+ or β0 Thalassemia
Intervention:
34 Recruiting Fetal Hemoglobin Induction Treatment Metformin
Conditions: Sickle Cell Anemia;   Sickle Cell Disease;   Hemoglobin Disorder;   Hemoglobin Disease; Sickle-Cell, Thalassemia
Intervention: Drug: Metformin
35 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune )
36 Recruiting CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease
Conditions: Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
Intervention: Biological: CD34 Stem Cell Selection Therapy
37 Recruiting BMT Abatacept for Non-Malignant Diseases
Conditions: Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman-Diamond Syndrome;   Diamond-Blackfan Anemia;   Dyskeratosis-congenita;   Chediak-Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia Major;   Hemophagocytic Lymphohistiocytosis;   Sickle Cell Disease
Intervention: Drug: Abatacept
38 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Lymphoproliferative Syndrome;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
39 Recruiting Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Conditions: Chronic Kidney Disease;   Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Chronic Myelogenous Leukemia (CML);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkin's Lymphoma (NHL);   Hodgkin Disease;   Multiple Myeloma;   Myelodysplastic Syndrome (MDS);   Aplastic Anemia;   AL Amyloidosis;   Diamond Blackfan Anemia;   Myelofibrosis;   Myeloproliferative Disease;   Sickle Cell Anemia;   Autoimmune Diseases;   Thalassemia
Intervention: Procedure: Haploidentical Bone Marrow/Kidney
40 Not yet recruiting Sickle Cell Omega-3 Treatment Trial (SCOT Trial)
Condition: Sickle Cell Disease
Interventions: Drug: SC411;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-53) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.